221 related articles for article (PubMed ID: 21695255)
1. Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN.
Tanwar PS; Zhang L; Kaneko-Tarui T; Curley MD; Taketo MM; Rani P; Roberts DJ; Teixeira JM
PLoS One; 2011; 6(6):e20715. PubMed ID: 21695255
[TBL] [Abstract][Full Text] [Related]
2. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
[TBL] [Abstract][Full Text] [Related]
3. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
Zhai Y; Iura A; Yeasmin S; Wiese AB; Wu R; Feng Y; Fearon ER; Cho KR
Oncogene; 2011 Oct; 30(40):4152-62. PubMed ID: 21499300
[TBL] [Abstract][Full Text] [Related]
4. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.
Tanwar PS; Kaneko-Tarui T; Lee HJ; Zhang L; Teixeira JM
Carcinogenesis; 2013 Apr; 34(4):893-901. PubMed ID: 23276799
[TBL] [Abstract][Full Text] [Related]
5. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
Wu R; Hu TC; Rehemtulla A; Fearon ER; Cho KR
Clin Cancer Res; 2011 Dec; 17(23):7359-72. PubMed ID: 21903772
[TBL] [Abstract][Full Text] [Related]
6. A mouse model for endometrioid ovarian cancer arising from the distal oviduct.
van der Horst PH; van der Zee M; Heijmans-Antonissen C; Jia Y; DeMayo FJ; Lydon JP; van Deurzen CH; Ewing PC; Burger CW; Blok LJ
Int J Cancer; 2014 Sep; 135(5):1028-37. PubMed ID: 24474556
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression.
Laguë MN; Paquet M; Fan HY; Kaartinen MJ; Chu S; Jamin SP; Behringer RR; Fuller PJ; Mitchell A; Doré M; Huneault LM; Richards JS; Boerboom D
Carcinogenesis; 2008 Nov; 29(11):2062-72. PubMed ID: 18687666
[TBL] [Abstract][Full Text] [Related]
8. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
9. β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.
Ahmad I; Morton JP; Singh LB; Radulescu SM; Ridgway RA; Patel S; Woodgett J; Winton DJ; Taketo MM; Wu XR; Leung HY; Sansom OJ
Oncogene; 2011 Jan; 30(2):178-89. PubMed ID: 20818428
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
Hendrix ND; Wu R; Kuick R; Schwartz DR; Fearon ER; Cho KR
Cancer Res; 2006 Feb; 66(3):1354-62. PubMed ID: 16452189
[TBL] [Abstract][Full Text] [Related]
11. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
12. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
[TBL] [Abstract][Full Text] [Related]
15. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.
Jung SH; Hwang HJ; Kang D; Park HA; Lee HC; Jeong D; Lee K; Park HJ; Ko YG; Lee JS
Oncogene; 2019 Mar; 38(10):1639-1650. PubMed ID: 30337688
[TBL] [Abstract][Full Text] [Related]
16. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
[TBL] [Abstract][Full Text] [Related]
18. Pten Mutations Alter Brain Growth Trajectory and Allocation of Cell Types through Elevated β-Catenin Signaling.
Chen Y; Huang WC; Séjourné J; Clipperton-Allen AE; Page DT
J Neurosci; 2015 Jul; 35(28):10252-67. PubMed ID: 26180201
[TBL] [Abstract][Full Text] [Related]
19. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.
Zhai Y; Kuick R; Tipton C; Wu R; Sessine M; Wang Z; Baker SJ; Fearon ER; Cho KR
J Pathol; 2016 Jan; 238(1):21-30. PubMed ID: 26279473
[TBL] [Abstract][Full Text] [Related]
20. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.
Wu R; Baker SJ; Hu TC; Norman KM; Fearon ER; Cho KR
Am J Pathol; 2013 Apr; 182(4):1391-9. PubMed ID: 23499052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]